Syntaxin Ltd. is a newly formed biotechnology company focusing on discovery and development of new medicines derived from bacterial toxins to treat chronic diseases.
Hypersecretion of mucus into the airways is an important contributor to morbidity and mortality in many patients with severe chronic lung diseases, such as chronic obstructive pulmonary disorder (COPD), asthma and cystic fibrosis.
Current treatments for COPD are palliative and do not halt disease progression, and there is no specific treatment for the mucus hypersecretion.
In patients with COPD, levels of the mucins are increased in the respiratory mucus.
One possibility for inhibiting mucus secretion is to utilize the anti-secretory activity of proteases of clostridial neurotoxins, targeted to the mucin secreting cells of the airway using Syntaxin's novel recombinant proteins.
Syntaxin explored a number of peptide ligands to receptors known to be present on mucin secreting cells of the respiratory epithelium, and proteases from serotypes of botulinum neurotoxin known to cleave SNARE proteins found within these cells.
The target product profile for this programme is a recombinant therapeutic protein that can be administered on an infrequent basis by inhalation to patients with a mucus hypersecretory component to their chronic respiratory condition such as COPD.
Targeted: A549 cells which are carcinomic human alveolar basal epithelial cells. [Cause excessive production of Mucus!]
With: R ecombinant therapeutic protein “SXN 187” [Recombinaint A-subunit of BoTox.]